McGuireWoods Advises VLP Therapeutics in Financing for Cancer Vaccine Development

Series A Preferred Funding Will Speed Progress Toward Clinical Trials

April 22, 2021

McGuireWoods advised Maryland-based biotech company VLP Therapeutics, Inc. (VLPT) in raising $16 million in equity financing. VLPT is engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue and COVID-19 using VLPT’s proprietary platform technologies.

VLPT intends to use proceeds of the financing to fund research and development of a cancer treatment vaccine. Investors in the Series A preferred stock funding were comprised of institutional investors in Japan, including MIYAKO Capital, Sojitz Corporation and Konishiyasu Co., Ltd., as well as existing U.S. investors.

New York partner Seth T. Goldsamt led the McGuireWoods team representing VLPT. Counsel Felix Saratovsky in Chicago; partner Jon Neal in Richmond, Virginia; partner Patrick Rowan in Washington, D.C.; partner Taylor French, counsel Samantha Souza and associate Andrew Terjesen in Charlotte, North Carolina; and counsel Nova Harb in Jacksonville, Florida, also advised on the matter.

McGuireWoods previously advised VLPT in various equity and convertible note financings.

“We were proud to assist VLPT in this transaction, which represents an important milestone for the company and will help advance its promising work on innovative vaccines to potentially treat cancer and infectious diseases,” Goldsamt said.

McGuireWoods consistently ranks among the leading law firms for U.S. and global M&A deals and is a dominant player in private equity deals in the healthcare and life sciences industries.The firm earned top 10 rankings for U.S. and global M&A deals completed in 2020 in league tables published by Refinitiv and Bloomberg.